RATHBONES

RATHBONE GREENBANK GLOBAL SUSTAINABILITY FUND

MONTHLY UPDATE FEBRUARY 2025

30%

The second coming of President Donald Trump was widely expected to boost US stocks at the expense of the rest of the world. Things haven't quite worked out that way.

Since Trump's election, European stocks have roared higher – even the FTSE All-Share has gained to a lesser degree – while their American counterparts have tumbled (check out the chart below). Since the S&P 500 started selling off in mid-February, the companies that posted the best returns over the past two years have been hit hardest. In contrast, the businesses that had the worst performance have fared well in the past month – in fact, on average they are up by double digits.


EUROPEAN STOCKS SURGE, US STOCKS SLUMP SO FAR THIS YEAR



Source: FactSet; local currency total return indexed to 100 at 28 Feb 2020, data to 18 Mar 2025

After years of outperformance, an ever-growing proportion of the US stock market became devoted to the 'Magnificent Seven' tech companies. That has cannibalised the diversification of many investors – particularly those that invest passively through trackers. With America's trade and foreign policy causing waves, it seems that some investors have taken profits from companies that have posted some truly extraordinary gains over the past year or two. With fully a fifth of the FTSE World stock market index invested in these seven companies as of the end of February, global indices have suffered as well.

THE MAG 7 DROVE RETURNS IN 2024, THEY'VE DRAGGED THE MARKET LOWER IN 2025



Source: Bloomberg, Rathbones; USD total return to 4 Mar 2025

For every action, a reaction

America's more aggressive, transactional foreign policy has caused massive shifts in geopolitics this year. Certain immutable facts and alliances, built up over decades, have fractured almost overnight.

The main one is NATO, a collective security pact that relies on its 32 members being adamant that any attack on one would trigger immediate retaliation by the rest. The US's equivocation on this point has badly damaged the alliance, perhaps irreparably. But Trump has done more than just put the sledgehammer to an ageing bulwark against the shadow of a Cold War superpower. He has also told the rest of the world, in no uncertain terms, that trade and security will be different from now on.

Past performance should not be seen as an indication of future performance. The value of investments and the income from them may go down as well as up and you may not get back what you originally invested.

How the rest of the world reacts to these seismic shifts in geopolitics, trade, national objectives and government spending will have consequences reaching decades into the future. Take Germany, one of the main engines of Europe: It responded to Trump's equivocation on NATO with a proposal to amend its constitution and scrap its debt brake, allowing the creation of a 10-year €500 billion infrastructure fund and permitting essentially unlimited borrowing for defence budgets. If approved, this river of money could flow into a nation that has parched itself of infrastructure investment for years because of a commitment to straitened government finances.

Along with rearmament, it could help revitalise the German 'Mittelstand', a network of small industrial parts manufacturers that has faded since the Global Financial Crisis. That could give the whole Continent a much needed shot in the arm.

If passed, these German policies – along with EU-wide measures also in train – would amount to a complete change in direction for Europe, which has been saddled with underinvestment, anaemic economic growth and ultra-low interest rates relative to the rest of the world. Excitement about this pent-up growth potential is why European stocks have skyrocketed in the past couple of weeks. Expectations for greater government spending across the bloc – particularly in Germany – sent the 10-year German government bond yield, which is the benchmark for European borrowing costs, soaring from 2.39% to 2.80% in the first couple of weeks of March. It's hard to explain just how massive that move is.

This is a good example of how shocks and policy changes can have more dynamic effects than just 'good' or 'bad'. People and nations react and adapt, sometimes predictably, sometimes in ways that we can't foresee. This matters for businesses because it tends to widen or narrow the pool of partners you can work with, the regions you can operate in and the flows of investment you can capture or must contend with.

Adjusting our healthcare investments

We bought US credit rating agency **S&P Global** last month. S&P has demonstrated consistently high returns on the money it has invested in its business. This has remained true both in the good economic times and in the bad. S&P makes money by assessing the financial strength of companies and the bonds they issue. This means it should continue to benefit from high debt issuance over the next few years. It also majority owns S&P Dow Jones, which manages reams of financial indices used to benchmark and make investments. This makes S&P a natural beneficiary of the increased use of passive financial products, which use these indices. We think the business should be able to increase its revenue by more than American GDP in most years, and there's also a good opportunity to make its analytics division more profitable. A new CEO has a clear plan to boost returns and recent results have encouraged us to buy in.

We sold the rest of our position in German pharmaceutical business **Merck**. We had already reduced our holding and felt that its management was too slow fixing problems in China. We felt there was a risk that the company was holding too much spare inventory, which could further dampen returns. While Merck's valuation looks cheap, organic growth is proving harder to come by. We see plenty of attractive alternatives in the healthcare space, so we sold. We recycled that money into Luxembourg-based laboratory chain **Eurofins Scientific** and US supplier of diagnostic tools and reagents for laboratories **Bio-Techne**. We've had more healthcare investments than our FTSE World Index benchmark for some time. There are increasing signs of normalisation in global demand patterns after being subdued since 2022. Eurofins and Bio-Techne are both trading at prices that are much lower multiples of their profits than they have in the past. We believe this could reverse as headwinds slowly turn into potential tailwinds this year.

Meanwhile, we trimmed Canadian e-commerce platform **Shopify** and **RELX**, which publishes academic, medical and legal journals. Shopify has performed extremely well in the past six months as its management delivered on promises to grow both sales and profit margins. We think there's more to come, but we also thought it was prudent to take some profits. Equally, RELX has been an excellent long-term compounder of profits. Organic growth remains robust and we think the opportunity in its legal division is still under-priced. We just trimmed our position size after it had grown to more than 3% of our fund.

The direction of America

Trump's 'America First' platform of fewer foreign entanglements, higher tariffs, tax cuts, public spending cuts and lessened regulation was widely signposted ahead of time. Most investors expected these measures to boost American workers, juice consumption, encourage business investment and drive the dollar and US stocks higher. However, there was always the other side of the coin. That these policies – along with a clampdown on immigration, both illegal and legal – could refire inflation, clog up supply chains and generally make it harder or more expensive to do business.

This messy mix of policies – where it's difficult to know which countervailing forces will prevail – leaves a lot of tinder around for people to create whichever campfire tale they want to tell. Some people make the case that inflation is about to rip higher, leading the US Federal Reserve to abandon any further interest rate cuts it had hoped to make. Others say America is on the cusp of recession. Some argue both: that 'stagflation' (stagnant growth along with higher inflation and unemployment) is approaching. We think all three are unlikely.

Inflation has drifted around between 2.5% and 3.5% since it descended from its post-COVID peaks in mid-2023. We've long thought it would probably stick slightly above the 2% central bank target once it calmed down after the upheaval of the post-pandemic period rather than scoot below it. It ticked down in February from 3.0% to 2.8%, so it seems well within benign levels to us. Of course, there's nothing like a national meltdown over the stratospheric rise in the price of eggs to make everyone in America think all prices are headed for the moon. This is standard fare for inflation: sudden spikes in low-value but everyday products tend to skew people's views of overall inflation. Food is the example par excellence.

US GDP growth, while it's slowed recently from its red-hot run, is still at the average of the 2010s, which is a healthy level. The economy would need to do the equivalent of a handbrake turn to start shrinking in the next 12 months. There are some signs that households are reining in their spending and cuts to government employees could be encouraging some of this. But there are plenty of opportunities for them to find other work, if rising private job openings are anything to go by. And while businesses are getting a little nervous about the erratic Trump administration, US profits are still expected to grow at a decent clip in the first quarter (7%), albeit not as much as analysts had hoped as the year dawned (12%). Trump's blizzard of executive orders, attempts to cut back government staff and <u>escalation of a trade war with virtually everyone</u> has rattled allies, rivals and markets alike. It will take time for the effects to be felt in supply chains and economic data. Trump 2.0 could upend the US economy for sure. But we think it's not the most likely scenario and it would take much longer than markets are suggesting. Instead, we think it's more likely that the US economy continues to forge ahead, slower than in the recent past but at a reasonable clip. And if that accompanies a resurgent Europe after two decades of funk, that should support global demand for goods and services, which is what drives corporate profits in the long run. China's leaders also seem to have realised that they need to act decisively to help their nation break out of its property-bubble slump. If they continue to pour well-targeted support into their financial system, that adds yet another leg to underpin the world economy.

It's completely understandable to feel worried when markets start falling, especially when there's so much news and uncertainty flying around. But knee-jerk reactions can be harmful for long-term returns.



DAVID HARRISON Fund Manager

For more info on our fund, including factsheets, performance and fund manager views, please click <u>here</u>.

If you require further clarification on this commentary, then please contact your adviser or Rathbones at the contact details below.

Any views and opinions are those of the investment manager, and coverage of any assets held must be taken in context of the constitution of the fund and in no way reflect an investment recommendation. Past performance should not be seen as an indication of future performance. The value of investments and the income from them may go down as well as up and you may not get back what you originally invested.

Rathbones Asset Management

30 Gresham Street London EC2V 7QN +44 (0)20 7399 0000 Information line: +44 (0)20 7399 0399 ram@rathbones.com rathbonesam com Rathbones Asset Management Limited is authorised and regulated by the Financial Conduct Authority and a member of The Investment Association. A member of the Rathbones Group PIc. Registered office: 30 Cresham Street, London EC2V 7QN Registered in England No. 02376568.